Search research articles
Contact Us
Filters
Showing results (81-90 of 123) with videos related to
Page
of 13
Sort By:
Investigational New Drugs
|
August 10, 2024
A randomized phase 1 study of safety, tolerability, and pharmacokinetics of MK-1088, a novel dual adenosine receptor antagonist, in healthy adult participants
Pranav Gupta, Manash Chatterjee, Yeonil Kim, et al.
Journal of Cellular Biochemistry
|
March 8, 2017
GSK1904529A, a Potent IGF-IR Inhibitor, Reverses MRP1-Mediated Multidrug Resistance
Pranav Gupta, Meina Xie, Silpa Narayanan, et al.
Drug Discovery Today
|
June 8, 2019
Revisiting mTOR inhibitors as anticancer agents
Qiu-Xu Teng, Yunali V Ashar, Pranav Gupta, et al.
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy
|
November 25, 2018
Modulating ROS to overcome multidrug resistance in cancer
Qingbin Cui, Jing-Quan Wang, Yehuda G Assaraf, et al.
Recent Patents on Anti-Cancer Drug Discovery
|
May 20, 2025
B-9-8, a Novel Harman Dimer, Reverses ABCG2-mediated Chemotherapeutic Drug Resistance
Ruiqiang Zhao, Yan Wen, Chao-Yun Cai, et al.
International Journal of Molecular Sciences
|
August 25, 2019
Chk1 Inhibitor MK-8776 Restores the Sensitivity of Chemotherapeutics in P-glycoprotein Overexpressing Cancer Cells
Qingbin Cui, Chao-Yun Cai, Jing-Quan Wang, et al.
International Journal of Women'S Dermatology
|
September 6, 2023
Dermatologic care of patients with differences of sex development
Sarah Gold, Christina Huang, Rakan Radi, et al.
Frontiers in Pharmacology
|
October 26, 2018
Olmutinib (BI1482694/HM61713), a Novel Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Reverses ABCG2-Mediated Multidrug Resistance in Cancer Cells
Wei Zhang, Ying-Fang Fan, Chao-Yun Cai, et al.
Therapeutic Innovation & Regulatory Science
|
September 21, 2018
Novel Gastroretentive Controlled Release Formulations for Once-Daily Administration: Assessment of Clinical Feasibility and Formulation Concept for Raltegravir
Rajesh Krishna, Matthew L Rizk, Patrick J Larson, et al.
International Journal of Biological Sciences
|
September 23, 2022
MG53 inhibits cellular proliferation and tumor progression in colorectal carcinoma
Pranav Gupta, Haichang Li, Guan-Nan Zhang, et al.
Page
of 13
Search research articles
Search
Showing results (81-90 of 123) with videos related to
Sort By:
Page
of 13
Investigational New Drugs
|
August 10, 2024
A randomized phase 1 study of safety, tolerability, and pharmacokinetics of MK-1088, a novel dual adenosine receptor antagonist, in healthy adult participants
Pranav Gupta, Manash Chatterjee, Yeonil Kim, et al.
Journal of Cellular Biochemistry
|
March 8, 2017
GSK1904529A, a Potent IGF-IR Inhibitor, Reverses MRP1-Mediated Multidrug Resistance
Pranav Gupta, Meina Xie, Silpa Narayanan, et al.
Drug Discovery Today
|
June 8, 2019
Revisiting mTOR inhibitors as anticancer agents
Qiu-Xu Teng, Yunali V Ashar, Pranav Gupta, et al.
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy
|
November 25, 2018
Modulating ROS to overcome multidrug resistance in cancer
Qingbin Cui, Jing-Quan Wang, Yehuda G Assaraf, et al.
Recent Patents on Anti-Cancer Drug Discovery
|
May 20, 2025
B-9-8, a Novel Harman Dimer, Reverses ABCG2-mediated Chemotherapeutic Drug Resistance
Ruiqiang Zhao, Yan Wen, Chao-Yun Cai, et al.
International Journal of Molecular Sciences
|
August 25, 2019
Chk1 Inhibitor MK-8776 Restores the Sensitivity of Chemotherapeutics in P-glycoprotein Overexpressing Cancer Cells
Qingbin Cui, Chao-Yun Cai, Jing-Quan Wang, et al.
International Journal of Women'S Dermatology
|
September 6, 2023
Dermatologic care of patients with differences of sex development
Sarah Gold, Christina Huang, Rakan Radi, et al.
Frontiers in Pharmacology
|
October 26, 2018
Olmutinib (BI1482694/HM61713), a Novel Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Reverses ABCG2-Mediated Multidrug Resistance in Cancer Cells
Wei Zhang, Ying-Fang Fan, Chao-Yun Cai, et al.
Therapeutic Innovation & Regulatory Science
|
September 21, 2018
Novel Gastroretentive Controlled Release Formulations for Once-Daily Administration: Assessment of Clinical Feasibility and Formulation Concept for Raltegravir
Rajesh Krishna, Matthew L Rizk, Patrick J Larson, et al.
International Journal of Biological Sciences
|
September 23, 2022
MG53 inhibits cellular proliferation and tumor progression in colorectal carcinoma
Pranav Gupta, Haichang Li, Guan-Nan Zhang, et al.
Page
of 13